DekaBank Deutsche Girozentrale’s Nurix Therapeutics NRIX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,000	Closed	-$121K	–	1295
2023 Q1	$121K	Hold	14,000	–	–	﹤0.01%	1236
2022 Q4	$153K	Hold	14,000	–	–	﹤0.01%	1261
2022 Q3	$182K	Hold	14,000	–	–	﹤0.01%	1242
2022 Q2	$175K	Hold	14,000	–	–	﹤0.01%	1211
2022 Q1	$198K	Buy	14,000 +1,300	+10%	+$23.1K	﹤0.01%	1210
2021 Q4	$384K	Buy	12,700 +300	+2%	+$9.1K	﹤0.01%	1155
2021 Q3	$366K	Hold	12,400	–	–	﹤0.01%	1111
2021 Q2	$344K	Hold	12,400	–	–	﹤0.01%	1127
2021 Q1	$351K	Hold	12,400	–	–	﹤0.01%	1084
2020 Q4	$465K	Buy	+12,400	New	+$411K	﹤0.01%	1035

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

DekaBank Deutsche Girozentrale's NRIX Position: Q2 2023 in Review

DekaBank Deutsche Girozentrale sold out of Nurix Therapeutics (NRIX) in Q2 2023, closing a stake of 14,000 shares — an estimated $121K sold.

DekaBank Deutsche Girozentrale first reported a position in NRIX in Q4 2020 and held it in 10 quarters. The position peaked at $465K in Q4 2020. 126 funds tracked by Wall St. Rank hold NRIX as of Q2 2023.

DekaBank Deutsche Girozentrale reported no remaining Nurix Therapeutics position as of Q2 2023 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 14,000 Nurix Therapeutics shares in Q2 2023, an estimated $121K.
DekaBank Deutsche Girozentrale first reported a position in Nurix Therapeutics in Q4 2020 and held it in 10 quarters.
DekaBank Deutsche Girozentrale's Nurix Therapeutics position peaked at $465K in Q4 2020.
126 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2023.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2023, filed 25 Jul 2023.